Primary Biliary Cirrhosis – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Primary Biliary Cirrhosis – Pipeline Review, H2 2018’, provides an overview of the Primary Biliary Cirrhosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis

– The report reviews pipeline therapeutics for Primary Biliary Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Primary Biliary Cirrhosis therapeutics and enlists all their major and minor projects

– The report assesses Primary Biliary Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Primary Biliary Cirrhosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Albireo Pharma Inc

Arena Pharmaceuticals Inc

Biocad

Cadila Healthcare Ltd

CymaBay Therapeutics Inc

Dr. Falk Pharma GmbH

Eisai Co Ltd

Enanta Pharmaceuticals Inc

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

Intercept Pharmaceuticals Inc

Kowa Co Ltd

NGM Biopharmaceuticals Inc

Novartis AG

Tiziana Life Sciences Plc

Virobay Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Primary Biliary Cirrhosis Overview

Primary Biliary Cirrhosis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Biliary Cirrhosis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Biliary Cirrhosis Companies Involved in Therapeutics Development

Albireo Pharma Inc

Arena Pharmaceuticals Inc

Biocad

Cadila Healthcare Ltd

CymaBay Therapeutics Inc

Dr. Falk Pharma GmbH

Eisai Co Ltd

Enanta Pharmaceuticals Inc

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

GlaxoSmithKline Plc

Intercept Pharmaceuticals Inc

Kowa Co Ltd

NGM Biopharmaceuticals Inc

Novartis AG

Tiziana Life Sciences Plc

Virobay Inc

Primary Biliary Cirrhosis Drug Profiles

A-4250 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCD-085 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-6011 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDP-305 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elafibranor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etrasimod arginine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FFP-104 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

foralumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GKT-831 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9674 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2330672 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pemafibrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saroglitazar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar lysine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tropifexor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ursodiol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZG-5216 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Biliary Cirrhosis Dormant Projects

Primary Biliary Cirrhosis Product Development Milestones

Featured News & Press Releases

Jun 05, 2018: Court Appoints Faruqi & Faruqi As Lead Counsel For Class Action Against Intercept Pharmaceuticals

May 07, 2018: Genkyotex Announces Positive Outcome from Independent SMB's First Pre-Planned Review of GKT831's Phase 2 Trial in Primary Biliary Cholangitis

Mar 28, 2018: Enanta Pharmaceuticals Announces Poster Presentations on EDP-305 at ICL 2018

Mar 23, 2018: Intercept Announces Multiple New Ocaliva (obeticholic acid) Data Presentations at the International Liver Congress 2018

Nov 01, 2017: Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis

Apr 19, 2017: Intercept Announces New Ocaliva (obeticholic acid) and INT-767 Data to be Presented at EASL 2017

Apr 05, 2017: Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2017

Feb 23, 2017: Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis

Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC

Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC

May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC

May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016

Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Primary Biliary Cirrhosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Primary Biliary Cirrhosis Pipeline by Albireo Pharma Inc, H2 2018

Primary Biliary Cirrhosis Pipeline by Arena Pharmaceuticals Inc, H2 2018

Primary Biliary Cirrhosis Pipeline by Biocad, H2 2018

Primary Biliary Cirrhosis Pipeline by Cadila Healthcare Ltd, H2 2018

Primary Biliary Cirrhosis Pipeline by CymaBay Therapeutics Inc, H2 2018

Primary Biliary Cirrhosis Pipeline by Dr. Falk Pharma GmbH, H2 2018

Primary Biliary Cirrhosis Pipeline by Eisai Co Ltd, H2 2018

Primary Biliary Cirrhosis Pipeline by Enanta Pharmaceuticals Inc, H2 2018

Primary Biliary Cirrhosis Pipeline by Genfit SA, H2 2018

Primary Biliary Cirrhosis Pipeline by GenKyoTex SA, H2 2018

Primary Biliary Cirrhosis Pipeline by Gilead Sciences Inc, H2 2018

Primary Biliary Cirrhosis Pipeline by GlaxoSmithKline Plc, H2 2018

Primary Biliary Cirrhosis Pipeline by Intercept Pharmaceuticals Inc, H2 2018

Primary Biliary Cirrhosis Pipeline by Kowa Co Ltd, H2 2018

Primary Biliary Cirrhosis Pipeline by NGM Biopharmaceuticals Inc, H2 2018

Primary Biliary Cirrhosis Pipeline by Novartis AG, H2 2018

Primary Biliary Cirrhosis Pipeline by Tiziana Life Sciences Plc, H2 2018

Primary Biliary Cirrhosis Pipeline by Virobay Inc, H2 2018

Primary Biliary Cirrhosis Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Primary Biliary Cirrhosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports